FTC Chairman To Be Jon Leibowitz: Will Reverse Payments Get More Scrutiny?
Executive Summary
Jon Leibowitz, a fierce opponent of reverse settlements between brand name and generic companies, is set to head the Federal Trade Commission
You may also be interested in...
The End Of Pay-For-Delay? FTC Sees An Opportunity In AndroGel Lawsuit
Reverse payment settlements are a popular tactic for settling patent disputes between brand companies and their generic competitors. The Federal Trade Commission has aggressively (but mostly unsuccessfully) fought “pay-for-delay” deals in the courts, arguing that they drive up drug prices. Now FTC has its best chance yet at convincing the Supreme Court to hear the issue. Is this the end of pay-for-delay?
Brand/Generic Settlements Return To Capitol Hill
Apotex could make its case for scrapping first-to-file exclusivity during a hearing in Rep. Rush’s subcommittee.
Politics Of Mega-Mergers: Health Reform And U.S. Biopharma Realignment
One theme tying together the two mega-mergers announced so far in 2009 is the sense that biopharma companies are taking defensive measures to prepare for health care reform in the U.S